Drug Shortage Report for TEVA-BUPRENORPHINE/NALOXONE
| Report ID | 221537 |
| Drug Identification Number | 02453916 |
| Brand name | TEVA-BUPRENORPHINE/NALOXONE |
| Common or Proper name | BUPRENORPHINE/NALOX 8/2MG |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | NALOXONE BUPRENORPHINE |
| Strength(s) | 2MG 8MG |
| Dosage form(s) | TABLET |
| Route of administration | SUBLINGUAL SUBLINGUAL |
| Packaging size | 30 |
| ATC code | N07BC |
| ATC description | DRUGS USED IN ADDICTIVE DISORDERS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2024-03-06 |
| Estimated end date | 2024-05-20 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2024-03-28 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2024-03-28 | French | Compare |
| v3 | 2024-03-28 | English | Compare |
| v2 | 2024-03-07 | French | Compare |
| v1 | 2024-03-07 | English | Compare |
Showing 1 to 4 of 4